Metoprolol in the treatment of cardiovascular disease: a critical reappraisal

References

• Facchini E, Degiovanni A, Cavallino C, et al. Beta-blockers and nitrates: pharmacotherapy and indications. Cardiovasc Hematol Agents Med Chem 2015;13:25-30
   PubMedGoogle Scholar
• Benfield P, Clissold SP, Brogden RN. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs 1986;31:376-429
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II). A randomized trial. Lancet 1999;353:9-13
   PubMed Web of Science ®Google Scholar
• The MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;352:2001-7
   Google Scholar
• Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-302
   PubMed Web of Science ®Google Scholar
• Flather MD, Gollop ND. Understanding mechanisms of action of beta-blockers in heart failure with reduced and preserved ejection fraction. JACC Heart Fail 2016;4:150-1
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975
   PubMed Web of Science ®Google Scholar
• Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40:491-8
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Colucci WS, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55
   PubMed Web of Science ®Google Scholar
• Wikstrand J, Wedel H, Castagno D, et al. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med 2014;275:134-43
   PubMed Web of Science ®Google Scholar
• Ghali JK, Wikstrand J, Van Veldhuisen DJ, et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). J Card Fail 2009;15:310-18
   PubMed Web of Science ®Google Scholar
• van Veldhuisen DJ, Aass H, El Allaf D, et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur J Heart Fail 2006;8:539-46
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Giles TD, Klibaner M, et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005;149:159-67
   PubMed Web of Science ®Google Scholar
• Herlitz J, Wikstrand J, Denny M, et al. Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension. J Card Fail 2002;8:8-14
   PubMed Web of Science ®Google Scholar
• Jánosi A, Ghali JK, Herlitz J, et al. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. Am Heart J 2003;146:721-8
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Gottlieb S, Ghali JK, et al. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004;25:1300-9
   PubMed Web of Science ®Google Scholar
• Ghali JK, Piña IL, Gottlieb SS, et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002;105:1585-91
   PubMed Web of Science ®Google Scholar
• Pasternak B, Svanström H, Melbye M, et al. Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure. JAMA Intern Med 2014;174:1597-604
   PubMed Web of Science ®Google Scholar
• Pasternak B, Mattsson A, Svanström H, et al. Comparative effectiveness of bisoprolol and metoprolol succinate in patients with heart failure. Int J Cardiol 2015;190:4-6
   PubMed Web of Science ®Google Scholar
• Fröhlich H, Zhao J, Täger T, et al. Carvedilol compared with metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failure: carvedilol or metoprolol evaluation study. Circ Heart Fail 2015;8:887-96
   PubMed Web of Science ®Google Scholar
• Colucci WS, Kolias TJ, Adams KF, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction. The REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007;116:49-56
   PubMedGoogle Scholar
• Green P, Anshelevich M, Talreja A, et al. Long-term effects of carvedilol or metoprolol on left ventricular function in ischemic and nonischemic cardiomyopathy. Am J Cardiol 2005;95:1114-16
   PubMed Web of Science ®Google Scholar
• Sigurdsson A, Held P, Swedberg K. Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J 1993;126:1068-76
   PubMed Web of Science ®Google Scholar
• Graham LN, Smith PA, Stoker JB, et al. Time course of sympathetic neural hyperactivity after uncomplicated acute myocardial infarction. Circulation 2002;106:793-7
   PubMed Web of Science ®Google Scholar
• Cohn JN. Neuroendocrine activation after acute myocardial infarction. Am J Cardiol 1990;65:28I-31I
   PubMed Web of Science ®Google Scholar
• Dézsi CA, Szentes V. The real role of β-blockers in daily cardiovascular therapy. Am J Cardiovasc Drugs 2017;17:361-73
   PubMed Web of Science ®Google Scholar
• Task Force Members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003
   PubMed Web of Science ®Google Scholar
• Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622-32
   PubMed Web of Science ®Google Scholar
• Ibanez B, Macaya C, Sánchez-Brunete V, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial. Circulation 2013;128:1495-503
   PubMed Web of Science ®Google Scholar
• Pizarro G, Fernández-Friera L, Fuster V, et al. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (effect of metoprolol in cardioprotection during an acute myocardial infarction). J am Coll Cardiol 2014;63:2356-62
   PubMed Web of Science ®Google Scholar
• Li J, Chen Z, Gao X, et al. Meta-analysis comparing metoprolol and carvedilol on mortality benefits in patients with acute myocardial infarction. Am J Cardiol 2017;120:1479-86
   PubMedGoogle Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20
   PubMed Web of Science ®Google Scholar
• Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34 [Internet]. National Clinical Guideline Centre (UK). London, UK: Royal College of Physicians (UK); 2011. National Institute for Health and Clinical Excellence: Guidance.
   Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:1269-1324.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357
   PubMed Web of Science ®Google Scholar
• Cruickshank JM. The role of beta-blockers in the treatment of hypertension. Adv Exp Med Biol 2017;956:149-66
   PubMed Web of Science ®Google Scholar
• Ripley TL, Saseen JJ. β-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother 2014;48:723-33
   PubMed Web of Science ®Google Scholar
• Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Database Syst Rev 2016;3:CD007451
   PubMedGoogle Scholar
• Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension 1991;17:579-88
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun N, Jiang X, et al. Comparative efficacy of β-blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysis. J Am Soc Hypertens 2017;11:394-401
   PubMed Web of Science ®Google Scholar
• Falkner B, Francos G, Kushner H. Metoprolol succinate, a selective beta-adrenergic blocker, has no effect on insulin sensitivity. J Clin Hypertens 2006;8:336-43
   Google Scholar
• Ambrosioni E. Pharmacoeconomic challenges in disease management of hypertension. J Hypertens 2001;14(suppl 3):S33-S40
   Google Scholar
• Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011;29:610-18
   PubMed Web of Science ®Google Scholar
• Frishman WH, Hainer JW, Sugg J, et al. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the metoprolol succinate-felodipine antihypertension combination trial (M-FACT). Am J Hypertens 2006;19:388-95
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Degl' Innocenti A, Elmfeldt D, et al. Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction. Am J Hypertens 2005;18:1313-19
   PubMed Web of Science ®Google Scholar
• Paz MA, de-La-Sierra A, Sáez M, et al. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine 2016;95:e4071
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962
   PubMed Web of Science ®Google Scholar
• Jouven X, Empana JP, Escolano S, et al. Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. Am J Cardiol 2009;103:279-83
   PubMed Web of Science ®Google Scholar
• Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-74
   PubMed Web of Science ®Google Scholar
• Ptaszynski P, Kaczmarek K, Ruta J, et al. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther 2013;18:338-44
   PubMed Web of Science ®Google Scholar
• Manolis AJ, Rosei EA, Coca A, et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension. J Hypertens 2012;30:239-52
   PubMed Web of Science ®Google Scholar
• Bertaglia E, D’Este D, Zerbo F, et al. Effects of verapamil and metoprolol on recovery from atrial electrical remodeling after cardioversion of long-lasting atrial fibrillation. Int J Cardiol 2003;87:167-72
   PubMed Web of Science ®Google Scholar
• Capucci A, Piangerelli L, Ricciotti J, et al. Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation. Europace 2016;18:1698-704
   PubMed Web of Science ®Google Scholar
• Skiba MA, Pick AW, Chaudhuri K, et al. Prophylaxis against atrial fibrillation after cardiac surgery: beneficial effect of perioperative metoprolol. Heart Lung Circ 2013;22:627-33
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri MT, Colombo A, et al. Prevention of atrial fibrillation in high-risk patients undergoing lung cancer surgery: the PRESAGE trial. Ann Surg 2016;264:244-51
   PubMed Web of Science ®Google Scholar
• Kamali A, Sanatkar A, Sharifi M, et al. Evaluation of amiodarone versus metoprolol in treating atrial fibrillation after coronary artery bypass grafting. Interv Med Appl Sci 2017;9:51-5
   PubMedGoogle Scholar
• Sun L, Yan S, Wang X, et al. Metoprolol prevents chronic obstructive sleep apnea-induced atrial fibrillation by inhibiting structural, sympathetic nervous and metabolic remodeling of the atria. Sci Report 2017;7:14941
   PubMed Web of Science ®Google Scholar
• Kühlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000;36:139-46
   PubMed Web of Science ®Google Scholar